You are here
Market Exclusivity Conferred for Tramadol ER by FDA
"Being the first-to-market with a once-daily formulation of tramadol is a significant competitive advantage," said Biovail Chief Executive Officer Dr. Douglas Squires. "The additional benefit of three years of market exclusivity only enhances the value of Tramadol ER."
Source: Biovail Corporation